stiripentol sold brand name diacomit anticonvulsant medication used treatment dravet syndrome serious genetic brain common side effects include loss appetite weight loss insomnia difficulty sleeping drowsiness ataxia inability muscle movements hypotonia low muscle strength dystonia muscle european union stiripentol indicated use conjunction clobazam valproate adjunctive therapy refractory generalized tonicclonic seizures people severe myoclonic epilepsy infancy smei dravets syndrome whose seizures adequately controlled clobazam united states stiripentol indicated treatment seizures associated dravet syndrome people two years age older taking clinical data support use stiripentol monotherapy dravet used countries addon therapy sodium valproate clobazam treating children dravet syndrome whose seizures adequately known whether stiripentol remains useful children become adolescents stiripentol must used people psychosis serious mental state distorted sense reality attacks delirium mental state confusion excitement restlessness common people adverse effects include loss appetite weight loss insomnia drowsiness ataxia hypotonia common people adverse effects include neutropenia sometimes severe aggressiveness irritability behavior disorders opposing behavior hyperexcitability sleep disorders hyperkinesias nausea vomiting elevated stiripentol inhibits several cytochrome isoenzymes interacts many anticonvulsants anticonvulsants precise mechanism action unknown regardless stiripentol shown anticonvulsant effects stiripentol increases gabaergic activity clinically relevant concentrations enhances central gaba neurotransmission barbituratelike effect since increases duration opening gabaa receptor channels hippocampal also shown increase gaba levels brain tissues interfering reuptake specifically shown inhibit lactate dehydrogenase important enzyme involved energy metabolism neurons inhibition enzyme make neurons less prone fire action potentials likely activation atpsensitive potassium stiripentol also improves effectiveness many anticonvulsants possibly due inhibition certain enzymes slowing drugs metabolism increasing blood plasma stiripentol Î±ethylene alcohol chemical formula chiral used medically racemate r enantiomer appears around times active stiripentol discovered scientists biocodex clinical trials started next originally developed adults focal seizures failed phase iii december european medicines agency ema granted stiripentol orphan drug status designation number treatment severe myoclonic epilepsy infancy smei also known dravets syndrome children january ema granted drug marketing authorisation use drug addon antiseizure approved canada use may also approved use august stiripentol approved us food drug administration fda adjunctive therapy dravet prior approval us parents children dravet syndrome paying around month supply obtain httpsenwikipediaorgwikistiripentol